Navigation Links
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
Date:7/22/2009

SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. A copy of Prima BioMed Ltd's public announcement follows.

New York (PRWEB) July 22, 2009 -- SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. To view a copy of Prima BioMed Ltd's public announcement please click here http://www.asx.com.au/asxpdf/20090721/pdf/31jn69xw14p8wy.pdf.

About KTA Capital, LLC
KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic co
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
2. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
3. Top CEOs Declare Americas Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership
4. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
5. Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Merck Serono Launches Strategic Venture Capital Fund
9. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
10. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
11. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... ON , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... period ended March 31, 2015.  Biorem,s complete 2015 first quarter financial ... Financial Summary:Three-months ended March 31,(in CDN$,000 except ... , 4,689 , 1,974 Gross profit , ... (318) Net earnings (loss) , 528 , ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner ... national innovative science curriculum for high school students focused ... 16 th annual LIFE Event (LPGA Pros in ... Ridge Country Club in West Caldwell, N.J. ... LPGA,s biggest stars raised more than $500,000 on Monday, ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Val Skinner Foundation Announces Partnership With Discovery Education 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... 2008, Abbott,s,( NYSE: ABT ) employee giving in the ... number of participating employees and total dollar contributions,despite difficult ... Abbott,employees (74 percent) participated in the company,s employee giving ... contributed more than $12.6,million to non-profit groups in 2008, ...
... Offering , ... Rochester, New York ... innovator in advanced cardiac safety biomakers and automated QT analysis, ... as its quarter over quarter revenues have grown in excess ...
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
Cached Biology Technology:Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 2Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 3iCardiac Reports Significant Revenue Growth and Profitability 2iCardiac Reports Significant Revenue Growth and Profitability 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... a new model to predict the impact of climate change ... Australia information that could help limit its spread. ... of the British Ecological Society,s journal Functional Ecology , ... and expand the mosquito,s range. But human behaviour in ...
... Institute at Arizona State University associate research scientist Melha Mellata, ... USDA funded project to develop a vaccine against a leading ... APEC is part of a large, diverse group ... They cause a number of complex brain, lung and urinary ...
... January 2009. The Alfred Wegener Institute for Polar ... conduct the ongoing Polarstern expedition LOHAFEX". Independent scientific ... of Education and Research and the Federal Ministry ... concluded that the iron fertilisation experiment LOHAFEX is ...
Cached Biology News:Hoarding rainwater could 'dramatically' expand range of dengue-fever mosquito 2New insights into a leading poultry disease and its risks to human health 2New insights into a leading poultry disease and its risks to human health 3New insights into a leading poultry disease and its risks to human health 4Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Zonula Adherens Sampler Kit 10 mu g each...
Golgi Sampler Kit 10g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: